Skip to main content
. 2018 Sep 11;9(9):923. doi: 10.1038/s41419-018-0948-4

Fig. 5. WS-iPSCs and WRN-ES cells are more sensitive to treatment of anticancer drug Camptothecin.

Fig. 5

a Percentages of apoptotic iPSCs treated with Camptothecin (CPT), Bleomycin, Brefeldin A, or H2O2. b Percentages of apoptotic ES cells treated with CPT, Bleomycin, Brefeldin A, or H2O2. * P < 0.005. c Cell cycle analysis after synchronization with nocodozal in the presence or absence of CPT. d, e Percentages of cells in S phase with CPT treatment at different time points (5, 9, and 13 h)